Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes

Pharmacogenetics. 2000 Apr;10(3):267-70. doi: 10.1097/00008571-200004000-00008.

Authors

J O Miners¹, S Coulter, D J Birkett, J A Goldstein

Affiliation

¹ Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University School of Medicine, Adelaide, Australia. john.miners@flinders.edu.au

PMID: 10803683
DOI: 10.1097/00008571-200004000-00008

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aryl Hydrocarbon Hydroxylases*
Cytochrome P-450 CYP2C9
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme System / genetics*
Diuretics / metabolism*
Enzyme Inhibitors / pharmacology
Genetic Variation*
Humans
Microsomes, Liver / enzymology
Saccharomyces cerevisiae / enzymology
Steroid 16-alpha-Hydroxylase*
Steroid Hydroxylases / antagonists & inhibitors
Steroid Hydroxylases / genetics*
Sulfaphenazole / pharmacology
Sulfonamides / metabolism*
Torsemide

Substances

Cytochrome P-450 Enzyme Inhibitors
Diuretics
Enzyme Inhibitors
Sulfonamides
cytochrome P-450 CYP2C subfamily
Sulfaphenazole
Cytochrome P-450 Enzyme System
Steroid Hydroxylases
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases
Steroid 16-alpha-Hydroxylase
Torsemide